Highlights:

LPI delivered ahead of schedule by as much as 12 months for one study

2 FDA approvals & 2 EMA approvals to date

Low turnover rate of just 15% for key staff

SummaryA Phase 2/3 study in relapsing multiple sclerosis patients was failing to recruit, so the sponsor engaged PSI to get enrollment back on track.We delivered Last Patient In (LPI) ahead of schedule – which led to us supporting a number of other studies in the sponsor’s portfolio. We’ve since completed recruitment in five other studies, each with LPI ahead of schedule. Most recently, we rescued enrollment in a global two-study ulcerative colitis pivotal program, delivering LPI a year sooner than expected.